John Engels - AxoGen Insider

AXGN -- USA Stock  

USD 35.50  0.50  1.39%

Mr. John P. Engels is Vice President of AxoGen, Inc., since September 30, 2011. He is a cofounder of AC and has served as ACs Vice President since June 2006, having provided operational and financial leadership and managing AxoGens strategic and product development partnerships until January 2012 when he assumed the leadership of international sales. From 1999 to 2002, Mr. Engels worked as a consultant for the University of Florida, Saffron Hill Ventures and PA Early Stage Partners, among other companies. From 1993 to 1997, Mr. Engels was an analyst and associate at CACM, a boutique investment banking firm. Mr. Engels is currently a member of the board of directors of Oxicool, Inc., a privatelyheld company developing new cooling technologies
Age: 44  Founder Since 2011  MBA    
Engels holds a MBA in Management and Operations from the Wharton School of Business at the University of Pennsylvania, and a BA from the University of Chicago.

John Engels Latest Insider Activity

John Engels over six months ago via Macroaxis 
AxoGen exotic insider transaction detected

Management Efficiency

The company has return on total asset (ROA) of (8.06) % which means that it has lost $8.06 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (21.86) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 84.27 K in liabilities. AxoGen has Current Ratio of 15.6 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen operates under Medical Devices classification in USA and traded on BATS Exchange. It employs 184 people.AxoGen (AXGN) is traded on BATS Exchange in USA. It is located in FLORIDA U.S.A and employs 184 people. AxoGen is listed under Medical Equipment category by Fama And French industry classification.

AxoGen Leadership Team

Robert Rudelius, Independent Director
Angelo Scopelianos, Vice President - Research & Development
Peter Mariani, CFO
Mark Friedman, Vice President - Regulatory and Quality
John Engels, Co-Founder and VP
Jamie Grooms, Co-Founder, Chairman, Member of Audit Committee and Member of Governance and Nominating Committee
Shawn McCarrey, Sr. VP of Sales
Amy Wendell, Director
Kevin Leach, Vice President - Marketing
Joseph Mandato, Independent Director
Mike Donovan, Director of Operations
Erick DeVinney, Vice President of Clinical and Translational Sciences
Lisa Colleran, Director
Karen Zaderej, CEO and President and Director
Kaila Krum, Vice President Investor Relations and Corporate Development
Gregory Freitag, Senior Vice President - Business Development, General Counsel, Director
David Hansen, Corporate Controller
Guido Neels, Director
Jon Gingrich, Chief Commercial Officer
Mark Gold, Independent Director
James Grooms, Independent Chairman of the Board

Stock Performance Indicators

Current Sentiment - AXGN

AxoGen Investor Sentiment

Most of Macroaxis users are presently bullish on AxoGen. What is your sentiment towards investing in AxoGen? Are you bullish or bearish?
98% Bullish
2% Bearish

AxoGen Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for AxoGen and Edwards Lifesciences. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Coins and Tokens Correlation module to utilize digital token correlation table to build portfolio of cryptocurrencies across multiple exchanges.